logo IDIBELL
Català  |   Castellano  |   English
Cerca
L'InstitutRecercaActualitatPlataformesUneix-te a nosaltresEines
 

Transformació i metàstasi

imatge Central Grup Recerca

Equip científic

Enllaços



Línies d'investigació

  • Estudi dels mecanismes que condueixen a la transformació cel·lular i que confereixen capacitat metastàtica a les cèl·lules epitelials de mama
  • Estudi de les vies de senyalització de cèl·lules progenitor
  • Paper de RANK en càncer de mama

Publicacions

 

Byrne AT, Alférez DG., Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek M, Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH,. Palmer HG, Peeper DS, Pelicci PG, Piris A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A and Trusolino L. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. In press. Nature Reviews Cancer.

 

Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, Dougall WC, Muñoz P, Pujana MA, Planelles L and González-Suarez E. RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res. 2016. Oct 1;76(19):5857-5869.

 

Serra-Musach J; Mateo F; Capdevila-Busquets E; Ruiz de Garibay G; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Perez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana, MA. Cancer network activity associated with therapeutic response and synergism.  Genome Medicine 2016 Aug 24;8(1):88.

 

Sigl V, Owusu-Boaitey K, Purna AJ, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA for CIMBA, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EYHP, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP and Penninger. JM. RANKL/RANK control Brca1-driven mammary tumors. Cell Res. 2016 Jul;26(7):761-74

 

da Silva-Diz V, Simón-Extremera P, Bernat-Peguera A, de Sostoa J, Ms. Urpí M, Dr. Penin RM , Pérez-Sidelnikova D, Bermejo O, Dr. Viñals JM , Rodolosse A, Gonzalez-Suarez E, Gómez Moruno A, Pujana MA, Esteller M, Dr. Villanueva A, Viñals F, Muñoz P. Cancer stem cell regulation changes at late stages of skin carcinoma progression to enhance tumor growth and metastasis. Cancer Res. 2016 Mar 1;76(5):1245-59.

 

Gonzalez-Suarez E & Sanz-Moreno A. Rank as a therapeutic target in cancer. FEBS J, 2016. FEBS J. 2016 Jun;283(11):2018-33

 

Cordero A*, Pellegrini P*, Sanz-Moreno A, Trinidad EM, Serra-Musach J, Deshpande C, Dougall WC, Pujana MA and González Suarez E. Rankl prevents lactogenesis through inhibition of the prolactin/Stat5 pathway.  Stem Cells. 2016 Apr;34(4):1027-39.

 

Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget. 2015 Dec 29;6(42):44254-73.

 

Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS One. 2015 Jun 24;10(6):e0131241. IF: 3.53

 

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. Plos One Jun 24;10(6) 2015. IF: 3.53

 

García-Castro A, Zonca M, Florindo-Pinheiro D, Carvalho-Pinto CE, Cordero A, Gutiérrez Del Burgo B, García-Grande A, Mañes S, Hahne M, González-Suárez E, Planelles L. APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. Carcinogenesis 2015 May;36(5):574-84. 2015 IF: 5,26

 

Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, Vizoso M, Martinez-Cardus A, Sayols S, Ferreira H, Sanchez-Mut J, Moran S, Margeli M, Castella E, Berdasco M, Stefansson OA, Eyfjord JE, Gonzalez-Suarez E, Dopazo J, Orozco M, Gut I, Esteller M. A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition. Cancer Res. 2014 Oct 1;74(19):5608-19.IF: 9.329

 

 H Heyn, S Sayols, C Moutinho, E Vidal, JV Sanchez-Mut, OA Stefansson, E Nadal, S Moran, E Gonzalez-Suarez, MA Pujana and M Esteller. Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk. Cell Reports 2014 Apr 24;7(2):331-8. IF: 8.358

 

WC Dougall, Gonzalez Suarez E, Holen I. (2014). Targeting RANKL in metastasis. BoneKey Rep 2014 April 9; 3, 519. 

 

P Pellegrini, A Cordero, MI Gallego, WC Dougall, P Muñoz, MA Pujana and E Gonzalez-Suarez. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells. 2013 Sep;31(9):1954-65. IF: 7,7

 

C Muñoz-Pinedo, E González-Suárez, A Portela, A Gentilella, M Esteller.. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of Personalized Medicine. Cancer Research. 2013 Jul 15;73(14):4185-4189. Epub 2013 May 17. IF: 8,6

 

V da Silva-Diz, S Solé-Sánchez, A Valdés-Gutiérrez, M Urpí, D Riba-Artés, RM. Penin, G Pascual, E González-Suárez, O Casanovas, F Viñals, J Paramio, E Batlle and P Muñoz  (2013). Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. Oncogene. 2013 Aug 8;32(32):3732-43. IF: 7,3

 

M Palafox, I Ferrer, P Pellegrini, S Vila, S Hernandez-Ortega, A Urruticoechea, F Climent, MT Soler, P Muñoz, F Viñals, M Tometsko, D Branstetter, WC. Dougall and González-Suárez E *. (2012). RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.Cancer Res. 2012 Jun 1;72(11):2879-88. Epub 2012 Apr 10. IF: 8,6

 

Tarragona M, Pavlovic M, Arnal-Estape A, Urosevic J, Morales M, Guiu M, Planet E, González-Suárez E, Gomis RR. (2012). Identification of NOG as a specific breast cancer bone metastasis-supporting gene.J Biol Chem. 2012 Jun 15;287(25):21346-55. Epub 2012 Apr 30. IF: 5,6

 

N Bonifaci, M Palafox, P Pellegrini, A Osorio, J Benítez, P Peterlongo, S Manoukian, B Peissel, D Zaffaroni, G Roversi, M Barile, A Viel, F Mariette, L Bernard, P Radice, B Kaufman, Y Laitman, R Milgrom, E Friedman, ME Sáez, J Climent, MT Soler, J Brunet, I Blanco, C Lázaro, V Moreno, A Urruticoechea, MA Pujana* and E González-Suárez*. Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Research Treatment, 2011. Oct;129(3):947-54. both authors contributed equally; * co.corresponding authors. IF: 4,8

 

González-Suárez E (2011). RANKL inhibition, a promising novel strategy for breast cancer treatment. Clin Trans Onc. 2011 Apr;13(4):222-8. Review. IF: 1,3

 

 Gonzalez-Suarez, E.*, Jacob, A.*, Jones, J., Miller, R., Roudier-Meyer, M., Erwert, R., Pinkas, J., Branstetter, D., and Dougall, WC. (2010). RANK Ligand Mediates Progestin-Induced Mammary Epithelial Proliferation and Carcinogenesis. Nature. 2010 Nov 4;468(7320):103-7. * both authors contributed equally to this work. IF: 36,1.

 

 Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M. (2010) BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors.J Clin Oncol. 2010 May 20;28(15):2512-9. IF: 17,8

 

González-Suárez, E., Branstetter, D., Armstrong, A., Dinh, H., Blumberg, H. and Dougall, W.C. (2007). RANK promotes mammary epithelial proliferation in MMTV-RANK mice and disrupts luminal formation in cultured acini. Mol. Cell. Biol. 27,1442-1454. # corresponding author. IF: 6.42,

 

Arnett, H.A., Escobar, S., González-Suárez, E., Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, and Viney J.A. (2007). BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J. Immunol. 178, 1523-1533. IF: 6.07.

 

Geserick, C., Tejera A., González-Suárez, E., Klatt, P. and Blasco, M.A. (2006). Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-β signaling. Oncogene. 2006 25 4310-4319. IF: 6,7.

 

González Suárez, E., Geserick C, Flores JM and Blasco, M.A (2005). Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. Oncogene. 2005 24, 2256-2270. IF:6,87. Citations: 51

 

González Suárez, E., Goytisolo FA, Flores JM, and Blasco, M.A (2003). Telomere dysfunction results in enhanced organismal sensitivity to the alkylating agent MNU. Cancer Res. 2003 63, 7047-7050. IF: 8,65.

 

González-Suárez, E., Flores, J.M. and Blasco M.A. (2002). Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development in mice. Mol. Cell. Biol. 2002 22, 7291-7301. IF: 8,84.

 

González-Suárez, E., Samper E, Ramírez A, Flores JM, Martín-Caballero J, Jorcano, J.L., and Blasco, M.A. (2001).  Increased epidermal tumors and increased wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001 2619-2630. IF: 12,46.

 

Sachsinger, J., González-Suárez, E., Samper E, Heicappell R, Müller M, and M.A. Blasco. (2001).  Effects of telomerase inhibition in a murine tumor cell line showing short telomeres, RenCa, by overexpression of a dominant negative mutant of mTert. Cancer Research 2001 61, 5580-5586. IF: 8,3.

 

Samper, E., Goytisolo FA, Ménissier-de Murcia J, González-Suárez E, Cigudosa JC, de Murcia G, Blasco MA. (2001). Normal telomere length and chromosomal end-capping in poly (ADP-ribose) polymerase deficient mice and primary cells despite increased chromosomal instability.  J. Cell Biol. 154, 2001 49-60. IF: 12,9. Citations: 69González-Suárez, E., Samper, E., Flores, J.M. and Blasco,.M.A. (2000). Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nature Genetics 2000 26, 114-117. IF 30,91.

ERC-2015- Consolidator Grant. LS4-682935 PLEIO-RANK Eva Gonzalez-Suarez (PI). European Research Council. 2016 - 2021            

 

SAF2014-55997-R. Therapeutic applications of RANKL inhibition in solid tumors: impact on tumor cells and tumor immune response. Eva Gonzalez-Suarez (PI and supervisor). Ministry of Economy and Finance. 2015 - 2017             

 

2014SGR513. Novel therapeuthic targets in epithelial cancer. Purificación Muñoz Moruno, Eva Gonzalez-Suarez (Co-PI). Generalitat de Catalunya. Recognized as a consolidated research group. 2014-2019

 

PIE13/00022. A PILOT STUDY FOR PERSONALIZED MEDICINE: ONCOPROFILE. Manel Esteller (Coordinator) Eva Gonzalez-Suarez (PI) Ministry of Economy and Finance. Integrated projects of excellence. Carlos III Healthy Institute. 2014 - 2017            

 

RANK signaling as a Novel Therapeutic Target inHer2+ and Her2 resistant breast cancerEva Gonzalez-Suarez (Coordinator and PI). Fundació La Marató de TV3. 2014 - 2016

 

CCR13262449RANK Pathway as a Novel Therapeutic Target in Human Breast Cancer.  Eva Gonzalez-Suarez (PI) Susan Komen Foundation Career Catalyst Research. 2013 - 2016 

 

SAF2011-22893

 

FMM Mutua Madrileña Foundation

 

Concern Foundation (USA)


AECC Catalunya


SAF-2008-01975

imatge personal
 

Cap de grup

Eva Gonzalez Suarez
Telèfon de contacte  
+34 932607347
Correu electrònic  
egsuarez@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Resultats per pàginaData inicial
Seleccionar data
TitolData final
Seleccionar data
Buscar


La vostra contrasenya està a punt de caducar. Si us plau, escriviu una nova contrasenya per seguir navegant

Recordeu que aquesta contrasenya us serveix per accedir a totes les aplicacions web de l’IDIBELL

Nova contrasenya:
Confirmar nova contrasenya:

Acceptar



La vostra contrasenya està a punt de caducar. Si us plau, escriviu una nova contrasenya per seguir navegant

Recordeu que aquesta contrasenya us serveix per accedir a totes les aplicacions web de l’IDIBELL

Nova contrasenya:
Confirmar nova contrasenya:

Acceptar


Cancel·lar

Les contrasenyes no coincideixen
La contrasenya ha de tenir com a mínim 6 caracters
La nova contrasenya no pot contenir caràcters especials
Registre d'usuari

Nom
1r Cognom
2n Cognom
Correu electrònic
Usuari
Contrasenya
Idioma


Acceptar


Cancel·lar




Encara no heu confirmat l'asistencia al curs de programacio en R programat pel dia 29-30 de juny i 6-7 de juliol, la data limit per fer la confirmació es el dia 09/06/2017

Voleu confirmar l'asistencia ara?

No




Falta informació referent a les vostres dades personals i de contacte, necessària per mantenir les bases de dades de l’IDIBELL.

Desitgeu omplir el formulari ara?

No





Si su plau, recordeu introduir la previsió de vacances a l’aplicatiu

Acceptar

Cancel·lar